全部分类
  • MS023
    MS023的可视化放大

    MS023

    An inhibitor of type I PRMTs

    此产品仅用于科学研究,我们不为任何个人用途提供产品和服务

    MS023的二维码
    • 库存: 现货
    可选规格
    • 包装
      价格
      促销价
      数量
    • 5mg
      ¥825.00
      660.00
      - +
    • 25mg
      ¥2612.00
      2090.00
      - +
    已选 0 0
    金额: ¥0.00
    首页 收藏
    • 货号: ajci4440
    • CAS: 1831110-54-3
    • 别名: N1-甲基-N1-[[4-[4-(异丙氧基)苯基]-1H-吡咯-3-基]甲基]-1,2-乙二胺
    • 分子式: C17H25N3O
    • 分子量: 287.4
    • 纯度: >98%
    • 溶解度: ≥ 28.7mg/mL in DMSO
    • 储存: Store at -20°C
    • 库存: 现货

    Background

    MS023 is a potent, selective, and cell-active inhibitor of type I protein arginine methyltransferases (PRMTs) [1]. with IC50s of 30, 119, 83, 4 and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, respectively [1].


    MS023 treatment (48 h exposure) potently and concentration dependently reduced cellular levels of H4R3me2a (IC50 = 9 ± 0.2 nM), PRMT1 is the main contributor to H4R3 (histone H4 arginine 3) asymmetric dimethylation (H4R3me2a) in cells. MS023 (20 h exposure) concentration dependently reduced the H3R2me2a mark in HEK293 cells (IC50 = 56 ± 7 nM), PRMT6 robustly increased endogenous asymmetric dimethylation of H3R2 (histone H3 arginine 2) [1]. MS023 (1μM, 24h) significantly reduced SARS-CoV-2 replication in VeroE6 cells by inhibition of arginine methylation [2]. MS023 (150,175,200μM) for 48 h treated DLD1 and HCT116 cells increased levels of active form of caspase 3 and PARP degradation as representative apoptosis-related proteins [3].


    MS023 treatment on mice model of spinal muscular atrophy (SMA) with both 2 mg/kg and 5 mg/kg resulted in significant increase in survival, with the 2 mg/kg dose achieving the best effect (median: 10 days), compared to both untreated (median: 7) and vehicle-treated (median: 6 days) mice. Mice treated with MS023 also showed an improvement in the disease-associated weight loss [4]. Once-daily dosing of 60 mg kg-1 MS023 initiated in mice with palpable tumors significantly reduced tumor growth and final tumor weight on MDA-MB-468 xenograft mice [5].

    参考文献:
    [1]. Eram M S, Shen Y, Szewczyk M M, et al. A potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases[J]. ACS chemical biology, 2016, 11(3): 772-781.
    [2]. Cai T, Yu Z, Wang Z, et al. Arginine methylation of SARS-Cov-2 nucleocapsid protein regulates RNA binding, its ability to suppress stress granule formation, and viral replication[J]. Journal of Biological Chemistry, 2021, 297(1).
    [3]. Lim Y, Lee J Y, Ha S J, et al. Proteome-wide identification of arginine methylation in colorectal cancer tissues from patients[J]. Proteome Science, 2020, 18(1): 1-11.
    [4]. Kordala A J, Ahlskog N, Hanifi M, et al. Type I PRMT inhibitor MS023 promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue the phenotype of SMA mice[J]. bioRxiv, 2022.
    [5]. Wu Q, Nie D Y, Ba-Alawi W, et al. PRMT inhibition induces a viral mimicry response in triple-negative breast cancer[J]. Nature Chemical Biology, 2022: 1-10.


    MS023 是 I 型蛋白精氨酸甲基转移酶 (PRMT) 的有效、选择性和细胞活性抑制剂[1]。 PRMT1、PRMT3、PRMT4、PRMT6 和 PRMT8 的 IC50 分别为 30、119、83、4 和 5 nM [1]


    MS023 处理(暴露 48 小时)有效且浓度依赖性地降低 H4R3me2a 的细胞水平(IC50 = 9 ± 0.2 nM),PRMT1 是细胞中 H4R3(组蛋白 H4 精氨酸 3)不对称二甲基化 (H4R3me2a) 的主要贡献者。 MS023(暴露 20 小时)浓度依赖性降低 HEK293 细胞中的 H3R2me2a 标记(IC50 = 56 ± 7 nM),PRMT6 显着增加 H3R2(组蛋白 H3 精氨酸 2)的内源性不对称二甲基化 [1]。 MS023(1μM,24 小时)通过抑制精氨酸甲基化显着降低 SARS-CoV-2 在 VeroE6 细胞中的复制 [2]。 MS023 (150,175,200μM) 处理 DLD1 和 HCT116 细胞 48 小时后,作为代表性的细胞凋亡相关蛋白 [3],可增加 caspase 3 活性形式和 PARP 降解的水平。


    MS023 以 2 mg/kg 和 5 mg/kg 的剂量处理脊髓性肌萎缩症 (SMA) 小鼠模型可显着提高存活率,其中 2 mg/kg 的剂量达到最佳效果(中位数:10 天) ,与未处理(中位数:7)和载体处理(中位数:6 天)的小鼠相比。接受 MS023 治疗的小鼠在与疾病相关的体重减轻方面也有所改善[4]。在 MDA-MB-468 异种移植小鼠上,每天一次给予 60 mg kg-1 MS023 可显着降低肿瘤生长和最终肿瘤重量[5]

    Protocol

    Cell experiment [1]:

    Cell lines

    Two human colon carcinoma cell lines DLD1 and HCT116

    Preparation Method

    CRC cells were seeded into 96-well plates at a density of 5 × 103 cells in 100 μl medium per well and cultured in 5% humidified atmosphere at 37 °C. After 24 h incubation, MS023 alone or combined with SN-38 was treated with increasing concentrations for 2 days.

    Reaction Conditions

    0-200μM for 2 days

    Applications

    Concentration of MS023 (125 μM) which resulted in about 40% reduction of CRC cell growth, MS023 significantly enhanced SN-38 cytotoxicity in DLD1 and HCT116 cells.

    Animal experiment [2]:

    Animal models

    Severe combined immunodeficient mice

    Preparation Method

    7?×?106 MDA-MB-468 cells were injected into the mice, MS023 was prepared at 5% N-Methyl-2-pyrrolidone (NMP), 20% captisol (wt/vol), 20% PEG-400 and 55% normal saline and administered to the mice by intraperitoneal injection. Tumors grown to a detectable size, as assessed by palpation (~2?mm in diameter), and started to treat with 60?mg kg–1 MS023 daily for a total of 5 weeks.

    Dosage form

    Intraperitoneal injection, 60 mg kg-1d-1 for 5 weeks.

    Applications

    Once-daily dosing of 60 mg kg-1 MS023 initiated in mice with palpable tumors significantly reduced tumor growth and final tumor weight.

    参考文献:

    [1]: Lim Y, Lee J Y, Ha S J, et al. Proteome-wide identification of arginine methylation in colorectal cancer tissues from patients[J]. Proteome Science, 2020, 18(1): 1-11.
    [2]: Wu Q, Nie D Y, Ba-Alawi W, et al. PRMT inhibition induces a viral mimicry response in triple-negative breast cancer[J]. Nature Chemical Biology, 2022: 1-10.

    此商品暂时还没有评价哦~

    温馨提示 ×
    商品已成功加入购物车!
    购物车共 0 件商品
    去购物车结算
    回到顶部